GlobeNewsWire
11 Dec 2025, 18:00 UTC · 48w ago
MAIA's Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates
Impact · against what's priced in
MAIA is a potential catalyst play following the initiation of a pivotal Phase 3 trial and receipt of FDA Fast Track designation for its first-in-class telomere-targeting therapy, ateganosine. The ability to create a new therapeutic category in the NSCLC market provides significant upside potential if clinical success is confirmed.
- MAIA+0.70
No priced-in read yet





